Introduction

When people hear the word “Wegovy,” weight loss is usually the first thing that comes to mind. And for good reason — semaglutide, the active ingredient in Wegovy, has transformed outcomes for those struggling with obesity.

But Wegovy’s benefits don’t stop at the number on the scale. Thanks to a growing body of clinical research and new Health Canada approvals, we now know that Wegovy directly supports metabolic health — including its newly approved use for a serious liver condition known as MASH.

Here’s why Wegovy is more than just a weight loss medication — and how it may benefit patients across Ontario with or without a high BMI.

What Is Wegovy, and How Does It Work?

Wegovy (semaglutide 2.4 mg) is a once-weekly GLP-1 receptor agonist medication originally approved in Canada for chronic weight management in adults who are obese or overweight with at least one weight-related condition (like diabetes, high blood pressure, or high cholesterol).

It works by mimicking the GLP-1 hormone in your body, which helps:

• Reduce appetite and food cravings
• Slow stomach emptying to help you feel fuller longer
• Regulate blood sugar levels
• Support meaningful weight loss (≥10–15% of body weight in many cases)

But now, Wegovy is being recognised for something even more impactful: directly reducing liver inflammation caused by metabolic dysfunction.

New Health Canada Approval: Wegovy for Non-Cirrhotic MASH

As of December 2025, Health Canada has approved a new use for Wegovy under a Notice of Compliance with Conditions (NOC/c):

Treatment of non-cirrhotic MASH (metabolic dysfunction–associated steatohepatitis) in adults with moderate to advanced liver fibrosis (F2–F3)

What is MASH?

MASH (previously known as NASH or non-alcoholic steatohepatitis) is a form of fatty liver disease caused by metabolic dysfunction, not alcohol. It involves:

• Fat accumulation in the liver
• Ongoing inflammation
• Cellular injury
• Progressive scarring (fibrosis)

Left untreated, MASH can lead to cirrhosis, liver failure, and cardiovascular disease.

What Makes This Approval Significant?

• MASH treatment no longer depends on BMI — patients don’t need to be obese to be eligible
• Cirrhosis (F4) is excluded — treatment is for those in F2–F3 stages of fibrosis
• Applies to diverse populations — including South Asian, Black, and Central Asian groups, who may develop fatty liver at lower weights

This marks a turning point in how we view metabolic health: weight is only part of the picture.

How Wegovy Helps Beyond Weight Loss

1. Reduces Liver Inflammation and Fat

Wegovy has been shown to directly lower liver fat content and reduce inflammatory activity in liver cells. This is essential for resolving MASH and preventing further progression.

2. Improves Liver Fibrosis

In clinical trials, semaglutide increased the chances of reversing MASH and stabilising liver fibrosis in F2–F3 patients — offering hope where few treatment options previously existed.

3. Improves Metabolic Markers

Wegovy improves:

• Insulin resistance
• Fasting blood sugar
• Triglycerides and cholesterol
• Overall cardiovascular risk

These are major contributors to liver inflammation and scarring, even in people who don’t appear “overweight.”

Wegovy vs Ozempic: Why They’re Not the Same

Though both medications contain semaglutide, they are not interchangeable.

It’s important to use the right medication for the right condition.

Who Should Consider Wegovy for Metabolic Health?

Wegovy may be a good option if you:

• Have been diagnosed with non-cirrhotic fatty liver disease
• Are at risk for diabetes, insulin resistance, or heart disease
• Have fibrosis stage F2 or F3, but not cirrhosis
• Are part of an ethnic group (e.g., South Asian, Central Asian, Black) more susceptible to metabolic complications at lower BMIs
• Struggle with weight and elevated liver enzymes
• Want a therapy that addresses root metabolic dysfunction

Modest Medix at the Forefront of Evolving Care

At Modest Medix, we pride ourselves on staying ahead of the curve — not just in treatment, but in education, precision, and patient-first care. Dr. Saima and our ABOM-certified team closely monitor Health Canada updates, clinical trials, and evolving guidelines to ensure every patient receives cutting-edge support.

We already offer medically supervised Wegovy programs for weight loss, and now we’re integrating the latest MASH indication to help even more patients benefit — including those who may not meet traditional weight criteria.

Whether you’re struggling with metabolic health, liver inflammation, or weight resistance, we don’t just follow trends — we lead with science.

Let’s treat the whole picture — not just the weight.
Reach out to our team to see if Wegovy is the right fit for your metabolic journey.

Written by the Modest Medix Clinic Team | Reviewed by Dr. Saima Khan (Dr. Eskay)